Raymond James Financial
VRTX icon

Raymond James Financial’s Vertex Pharmaceuticals VRTX Stock Holding History

Raymond James Financial’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$198M Buy
444,496
+26,365
+6% +$12.3M 0.06% 281
2025
Q4 		$190M Sell
418,131
-117,554
-22% -$50.7M 0.06% 286
2025
Q3 		$210M Buy
535,685
+35,908
+7% +$15M 0.07% 260
2025
Q2 		$223M Sell
499,777
-10,765
-2% -$4.96M 0.08% 230
2025
Q1 		$248M Buy
510,542
+38,636
+8% +$18M 0.09% 205
2024
Q4 		$190M Buy
+471,906
New +$219M 0.07% 250

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Raymond James Financial's VRTX Position: Q1 2026 in Review

Raymond James Financial increased its Vertex Pharmaceuticals (VRTX) stake by 6.3% in Q1 2026, buying an estimated $12.3M and bringing the position to 444,496 shares worth $198M. The position accounts for 0.06% of the portfolio, ranked #281.

Raymond James Financial first reported a position in VRTX in Q4 2024 and has held it in 6 quarters since. The position peaked at $248M in Q1 2025. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • Raymond James Financial held 444,496 shares of Vertex Pharmaceuticals worth $198M as of Q1 2026.
  • Raymond James Financial bought 26,365 Vertex Pharmaceuticals shares in Q1 2026, an estimated $12.3M.
  • Vertex Pharmaceuticals made up 0.06% of Raymond James Financial's portfolio in Q1 2026, its #281 holding.
  • Raymond James Financial first reported a position in Vertex Pharmaceuticals in Q4 2024 and has held it in 6 quarters since.
  • Raymond James Financial's Vertex Pharmaceuticals position peaked at $248M in Q1 2025.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Raymond James Financial's 13F filing for Q1 2026, filed 14 May 2026.